MedPath

Prasugrel

Generic Name
Prasugrel
Brand Names
Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)
Drug Type
Small Molecule
Chemical Formula
C20H20FNO3S
CAS Number
150322-43-3
Unique Ingredient Identifier
34K66TBT99
Background

Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.

Indication

用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。

Associated Conditions
Cardiovascular Events
Clinical Trials
Related News

Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment

Phase 3
Completed
Conditions
Coronary Artery Disease (CAD)
Interventions
First Posted Date
2011-02-25
Last Posted Date
2011-08-23
Lead Sponsor
University of Patras
Target Recruit Count
25
Registration Number
NCT01304472
Locations
🇬🇷

Dimitrios Alexopoulos, Patras, Greece

🇬🇷

Patras University Hospital Cardiology Department, Patras, Greece

The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2010-12-15
Last Posted Date
2019-01-09
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
110
Registration Number
NCT01260584
Locations
🇺🇸

Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States

🇺🇸

The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital, Cincinnati, Ohio, United States

🇺🇸

Sanai Center for Thrombosis Research, Baltimore, Maryland, United States

Prasugrel Re-load Strategies

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2010-09-15
Last Posted Date
2013-01-18
Lead Sponsor
University of Florida
Target Recruit Count
65
Registration Number
NCT01201772
Locations
🇺🇸

University of Florida, Jacksonville, Florida, United States

An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults

Phase 1
Completed
Conditions
Anemia, Sickle Cell
Interventions
First Posted Date
2010-08-09
Last Posted Date
2012-02-15
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
26
Registration Number
NCT01178099
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, UK, United Kingdom

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction.

Not Applicable
Completed
Conditions
Anti Platelet Effects
Interventions
Drug: Placebo
First Posted Date
2010-08-04
Last Posted Date
2012-07-04
Lead Sponsor
Ascopharm Groupe Novasco
Target Recruit Count
82
Registration Number
NCT01175200
Locations
🇫🇷

Pitié Salpétrière Hospital, Paris, France

Prasugrel Versus Placebo in Adult Sickle Cell Disease

Phase 2
Completed
Conditions
Sickle Cell Anemia
Interventions
Drug: Placebo
First Posted Date
2010-07-21
Last Posted Date
2012-05-03
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
62
Registration Number
NCT01167023
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States

Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis

Phase 3
Completed
Conditions
Chronic Renal Failure
Hemodialysis
Interventions
First Posted Date
2010-07-02
Last Posted Date
2010-11-16
Lead Sponsor
University of Patras
Target Recruit Count
70
Registration Number
NCT01155765
Locations
🇬🇷

Patras University Hospital, Patras, Achaia, Greece

Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI

Phase 4
Completed
Conditions
Coronary Artery Disease
Percutaneous Coronary Intervention
Acute Coronary Syndromes
Interventions
First Posted Date
2010-06-03
Last Posted Date
2012-10-04
Lead Sponsor
Lene Holmvang
Target Recruit Count
106
Registration Number
NCT01135667
Locations
🇩🇰

Rigshospitalet, Department of Cardiology, 2013, Copenhagen O, Denmark

Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients

Phase 2
Completed
Conditions
Acute Coronary Syndrome
Interventions
Drug: Placebo
First Posted Date
2010-05-04
Last Posted Date
2012-11-20
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
282
Registration Number
NCT01115738
Locations
🇮🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India

Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI).

Phase 3
Completed
Conditions
Coronary Artery Disease (CAD)
Acute Coronary Syndrome (ACS)
Interventions
First Posted Date
2010-04-23
Last Posted Date
2010-08-24
Lead Sponsor
University of Patras
Target Recruit Count
70
Registration Number
NCT01109784
Locations
🇬🇷

Cardiology Department, Patras University Hospital, Rio, Patras, Greece

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy